0
June 11, 1997, Vol 277, No. 22 >
ARTICLE | June 11, 1997

Users' Guides to the Medical Literature: Title and subTitle BreakXIII. How to Use an Article on Economic Analysis of Clinical Practice B. What Are the Results and Will They Help Me in Caring for My Patients? FREE

Bernie J. O'Brien, PhD; Daren Heyland, MD; W. Scott Richardson, MD; Mitchell Levine, MD; Michael F. Drummond, PhD
[+] Author Affiliations

The original list of members (with affiliations) appears in the first article of this series (JAMA. 1993;270: 2093-2095). A list of new members appears in the 10th article of the series (JAMA. 1996;275:1435-1439). The following members contributed to this article: Gordon H. Guyatt, MD, MSc (chair); Roman Jaeschke, MD, MSc; Deborah J. Cook, MD, MSc; Hertzel Gerstein, MD, MSc; Stephen Walter, PhD; John Williams, Jr, MD, MHS; and C. David Naylor, MD, MSc, DPhil.

Reprints: Gordon H. Guyatt, MD, MSc, McMaster University Health Sciences Centre, 1200 Main St W, Room 2C12, Hamilton, Ontario, Canada L8N 3Z5.

Users' Guides to the Medical Literature section editor: Drummond Rennie, MD, Deputy Editor (West), JAMA.


JAMA. 1997;277(22):1802-1806. doi:10.1001/jama.1997.03540460066034
Text Size: A A A
Published online
Article
References

CLINICAL SCENARIO  You recall from the first of our 2 articles1 concerning economic analysis of clinical practice that your chief of medicine has asked you to review relevant economic evidence from the literature and report to the hospital's pharmacy and therapeutics committee, which is trying to decide on formulary guidelines for the use of streptokinase and tissuetype plasminogen activator (t-PA) in the treatment of acute myocardial infarction (AMI). Your literature search identified 2 recent key cost-effectiveness studies: an analysis of economic data collected prospectively as part of the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) trial2 of streptokinase vs t-PA by Mark et al,3 and a decision-analytic model by Kalish et al.4 In the first article of this 2-part series we showed you how to evaluate the validity of the different economic appraisal study methods. In this article, we will

REFERENCES

1 +
Drummond MF, Richardson WS, O'Brien BJ, et al, for the Evidence-Based Medicine Working Group.  Users' guides to the medical literature, XIII: how to use an article on economic analysis of clinical practice, A: are the results of the study valid? JAMA . 1997;;277:1552-1557.
2 +
The GUSTO Investigators.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction . N Engl J Med . 1993;;329:673-682.
3 +
Mark DB, Hlatky MA, Califf RM, et al.  Costeffectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction . N Engl J Med . 1995;;332:1418-1424.
4 +
Kalish SC, Gurwitz JH, Krumholz HM, Avorn J.  Cost-effectiveness of model of thrombolytic therapy for acute myocardial infarction . J Gen Intern Med . 1995;;10:321-330.
5 +
Torrance GW, Feeny D.  Utilities and qualityadjusted life years . Int J Technol Assess Health Care . 1989;;5:559-575.
6 +
Richardson WS, Detsky AS, for the Evidence-Based Medicine Working Group.  Users' guides to the medical literature, VII: how to use a clinical decision analysis, A: are the results of the study valid? JAMA . 1995;;273:1292-1295.
7 +
Richardson WS, Detsky AS, for the Evidence-Based Medicine Working Group.  Users' guides to the medical literature, VII: how to use a clinical decision analysis, B: what are the results and will they help me in caring for my patients? JAMA . 1995;;273:1610-1613.
8 +
Mehrez A, Gafni A.  The healthy-years equivalents: how to measure them using the standard gamble approach . Med Decis Making . 1991;;11:140-146.
9 +
Lee TH.  Cost-effectiveness of tissue plasminogen activator . N Engl J Med . 1995;;332:1443-1444.
10 +
Ridker PM, O'Donnell C, Marder VT, Hennekens CH.  Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1 . Ann Intern Med . 1993;;119:530-532.
11 +
O'Brien BJ, Drummond MF, Labelle RJ, Willan A.  In search of power and significance: issues in design and analysis of stochastic cost-effectiveness studies in health care . Med Care . 1994;;32:150-163.
12 +
O'Brien BJ, Goeree R, Mohamed AH, Hunt R.  Cost-effectiveness of Helicobactor pylori eradication for the long-term management of duodenal ulcer in Canada . Arch Intern Med . 1995;;155:1958-1964.
13 +
Johannesson M, Weinstein MC.  On the decision rules of cost-effectiveness analysis . J Health Econ . 1993;;12:459-467.
14 +
Birch S, Gafni A.  Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems . J Health Econ . 1993;;12:469-476.
15 +
Drummond MF, Torrance GW, Mason J.  Cost-effectiveness league tables: more harm than good? Soc Sci Med . 1993;;37:33-40.
16 +
Guyatt GH, Sackett DL, Cook DJ, for the Evidence-Based Medicine Working Group.  Users' Guides to the Medical Literature, II: how to use an article about therapy or prevention, B: what were the results and will they help me in caring for my patient? JAMA . 1994;;271:59-63.
17 +
Ridker PM, O'Donnell C, Marder V, Hennekens CH.  A response to 'Holding GUSTO up to the light.' Ann Intern Med . 1994;;120:882-885.
18 +
Ridker PM, Manson J, Goldhaber SZ, Hennekens CH, Buring JE.  Comparison of delay times to hospital presentation for physicians and non-physicians with acute myocardial infarction . Am J Cardiol . 1992;;45:505-512.
19 +
Van de Werf F, Topol EJ, Lee KL, et al.  Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries . JAMA . 1995;;273:1586-1591.
20 +
Drummond MF, Bloom BS, Carrion G, et al.  Issues in the cross national assessment of health technology . Int J Technol Assess Health Care . 1992;; 8:671-682.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

1 +
Drummond MF, Richardson WS, O'Brien BJ, et al, for the Evidence-Based Medicine Working Group.  Users' guides to the medical literature, XIII: how to use an article on economic analysis of clinical practice, A: are the results of the study valid? JAMA . 1997;;277:1552-1557.
2 +
The GUSTO Investigators.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction . N Engl J Med . 1993;;329:673-682.
3 +
Mark DB, Hlatky MA, Califf RM, et al.  Costeffectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction . N Engl J Med . 1995;;332:1418-1424.
4 +
Kalish SC, Gurwitz JH, Krumholz HM, Avorn J.  Cost-effectiveness of model of thrombolytic therapy for acute myocardial infarction . J Gen Intern Med . 1995;;10:321-330.
5 +
Torrance GW, Feeny D.  Utilities and qualityadjusted life years . Int J Technol Assess Health Care . 1989;;5:559-575.
6 +
Richardson WS, Detsky AS, for the Evidence-Based Medicine Working Group.  Users' guides to the medical literature, VII: how to use a clinical decision analysis, A: are the results of the study valid? JAMA . 1995;;273:1292-1295.
7 +
Richardson WS, Detsky AS, for the Evidence-Based Medicine Working Group.  Users' guides to the medical literature, VII: how to use a clinical decision analysis, B: what are the results and will they help me in caring for my patients? JAMA . 1995;;273:1610-1613.
8 +
Mehrez A, Gafni A.  The healthy-years equivalents: how to measure them using the standard gamble approach . Med Decis Making . 1991;;11:140-146.
9 +
Lee TH.  Cost-effectiveness of tissue plasminogen activator . N Engl J Med . 1995;;332:1443-1444.
10 +
Ridker PM, O'Donnell C, Marder VT, Hennekens CH.  Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1 . Ann Intern Med . 1993;;119:530-532.
11 +
O'Brien BJ, Drummond MF, Labelle RJ, Willan A.  In search of power and significance: issues in design and analysis of stochastic cost-effectiveness studies in health care . Med Care . 1994;;32:150-163.
12 +
O'Brien BJ, Goeree R, Mohamed AH, Hunt R.  Cost-effectiveness of Helicobactor pylori eradication for the long-term management of duodenal ulcer in Canada . Arch Intern Med . 1995;;155:1958-1964.
13 +
Johannesson M, Weinstein MC.  On the decision rules of cost-effectiveness analysis . J Health Econ . 1993;;12:459-467.
14 +
Birch S, Gafni A.  Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems . J Health Econ . 1993;;12:469-476.
15 +
Drummond MF, Torrance GW, Mason J.  Cost-effectiveness league tables: more harm than good? Soc Sci Med . 1993;;37:33-40.
16 +
Guyatt GH, Sackett DL, Cook DJ, for the Evidence-Based Medicine Working Group.  Users' Guides to the Medical Literature, II: how to use an article about therapy or prevention, B: what were the results and will they help me in caring for my patient? JAMA . 1994;;271:59-63.
17 +
Ridker PM, O'Donnell C, Marder V, Hennekens CH.  A response to 'Holding GUSTO up to the light.' Ann Intern Med . 1994;;120:882-885.
18 +
Ridker PM, Manson J, Goldhaber SZ, Hennekens CH, Buring JE.  Comparison of delay times to hospital presentation for physicians and non-physicians with acute myocardial infarction . Am J Cardiol . 1992;;45:505-512.
19 +
Van de Werf F, Topol EJ, Lee KL, et al.  Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries . JAMA . 1995;;273:1586-1591.
20 +
Drummond MF, Bloom BS, Carrion G, et al.  Issues in the cross national assessment of health technology . Int J Technol Assess Health Care . 1992;; 8:671-682.

Letters

Submit a Letter
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

© 2012 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems